These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19500496)

  • 1. Review of the SPARCL trial and its subanalyses.
    Welch KM
    Curr Atheroscler Rep; 2009 Jul; 11(4):315-21. PubMed ID: 19500496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPARCL: the glimmer of statins for stroke risk reduction.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2007 Nov; 9(5):347-51. PubMed ID: 18001616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
    Huisa BN; Stemer AB; Zivin JA
    Vasc Health Risk Manag; 2010 Apr; 6():229-36. PubMed ID: 20407630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
    Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
    Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin in prevention of stroke and transient ischaemic attack.
    Amarenco P
    Expert Opin Pharmacother; 2007 Nov; 8(16):2789-97. PubMed ID: 17956199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
    Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Fitchett DH; Goodman SG; Langer A
    Can J Cardiol; 2008 Sep; 24(9):705-8. PubMed ID: 18787721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atorvastatin in secondary prevention].
    Ongen Z; Yilmaz Y; Karadağ B
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():23-8. PubMed ID: 19404047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
    N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
    Khan M; Kamran KA
    J Pak Med Assoc; 2010 Jun; 60(6):505-6. PubMed ID: 20527658
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
    Arrospide A; Mar J; Vivancos-Mora J; Rejas-Gutiérrez J; Caro J
    Rev Neurol; 2010 Jul; 51(1):1-11. PubMed ID: 20568062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
    Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
    Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Important aim of statin therapy: ischemic cardiovascular event (stroke)].
    Császár A
    Ideggyogy Sz; 2008 Jul; 61(7-8):239-43. PubMed ID: 18763479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Arca M
    Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.